Table Info

Table 1.

Clinical characteristics

Parameter	HIV⁺HCV⁺ DAA^– INRs	HIV⁺HCV^– DAA⁺ INRs	Healthy controls
Number of enrollments	10	9	10
Age (years)	41 (40–42)	43 (35–47)	41 (40–44)
Males (%)	50 p_HCV–DAA+ < 0.05	100 p_HC < 0.05	50
HIV-infection duration (years)	8.0 (6.5–10.0) p_HCV–DAA+ < 0.05	15.0 (10.0–20.5)	––
ART duration (years)	3.0 (2.0–4.7) p_HCV–DAA+ < 0.05	6.0 (5.0–11.0)	––
HIV viral load (copies/mL)	< 50^※	< 50^※	––
Time elapsed post-DAA therapy (months)	––	21.5 (20.0–27.3)	––

The data are presented as medians and interquartile ranges. ^※: the test-system sensitivity limit; ––: no data; ART: antiretroviral therapy; DAA: direct-acting antivirals; INRs: immunological non-responders. Significance of differences between groups was established based on the ANOVA test with Tukey’s corrections

Declarations

Author contributions

VV: Conceptualization, Investigation, Visualization, Writing—original draft. ES and LK: Conceptualization, Investigation, Writing—review & editing. NS: Project administration, Resources, Investigation. KS: Conceptualization, Validation, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The work described has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The work plan (No. 17-54-30006) was approved by the ethics committee of the Perm Regional Center for the Prevention and Control of AIDS and Infectious Diseases (committee registration number IRB00008964).

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This work was carried out within the framework of the State assignment #124021900006-5. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol. 2008;23:1000–8. [DOI] [PubMed]

Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797–808. [DOI] [PubMed]

Payagala S, Pozniak A. The global burden of HIV. Clin Dermatol. 2024;42:119–27. [DOI] [PubMed]

Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–9. [DOI] [PubMed]

Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management. Int J Drug Policy. 2007;18:426–32. [DOI] [PubMed]

Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362–71. [DOI] [PubMed] [PMC]

Brites-Alves C, Netto EM, Brites C. Coinfection by Hepatitis C Is Strongly Associated with Abnormal CD4/CD8 Ratio in HIV Patients under Stable ART in Salvador, Brazil. J Immunol Res. 2015;2015:174215. [DOI] [PubMed] [PMC]

Badano MN, Parodi C, Aloisi N, Corti M, Elizalde de Bracco MM, Baré P. Influence of Hepatitis C virus coinfection on immune reconstitution in HIV subjects. Med Microbiol Immunol. 2019;208:747–56. [DOI] [PubMed]

Macías J, Pineda JA, Lozano F, Corzo JE, Ramos A, León E, et al. Impaired Recovery of CD4⁺ Cell Counts Following Highly Active Antiretroviral Therapy in Drug-Naïve Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Eur J Clin Microbiol Infect Dis. 2003;22:675–80. [DOI] [PubMed]

10.

Battegay M, Nüesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006;6:280–7. [DOI] [PubMed]

11.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361–72. [DOI] [PubMed]

12.

Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, et al. CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Med. 2012;9:e1001194. [DOI] [PubMed] [PMC]

13.

Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13:267–76. [DOI] [PubMed] [PMC]

14.

Gianella S, Anderson CM, Var SR, Oliveira MF, Lada SM, Vargas MV, et al. Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol. 2016;90:3944–52. [DOI] [PubMed] [PMC]

15.

Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS. 2016;11:191–200. [DOI] [PubMed] [PMC]

16.

Shmagel KV, Korolevskaya LB, Saidakova EV, Shmagel NG, Chereshnev VA, Margolis L, et al. HCV coinfection of the HIV-infected patients with discordant CD4⁺ T-cell response to antiretroviral therapy leads to intense systemic inflammation. Dokl Biol Sci. 2017;477:244–7. [DOI] [PubMed] [PMC]

17.

Vlasova VV, Korolevskaya LB, Loginova O, Shmagel NG, Saidakova EV. Functional exhaustion of CD4⁺ T cells in HIV/HCV coinfected HAART-treated patients. Med Immunol. 2023;25:837–44. [DOI]

18.

Saidakova EV, Korolevskaya LB, Vlasova VV, Shmagel NG, Shmagel KV. Markers of CD4⁺ AND CD8⁺ T-cell exhaustion in HIV/HCV coinfected immunological non-responders to antiretroviral therapy. Russ J Infect Immun. 2024;14:586–92. [DOI]

19.

Feuth T, Arends JE, Fransen JH, Nanlohy NM, van Erpecum KJ, Siersema PD, et al. Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection. PLoS One. 2013;8:e59302. [DOI] [PubMed] [PMC]

20.

Shmagel KV, Saidakova EV, Korolevskaya LB, Shmagel NG, Chereshnev VA, Anthony DD, et al. Influence of hepatitis C virus coinfection on CD4⁺ T cells of HIV-infected patients receiving HAART. AIDS. 2014;28:2381–8. [DOI] [PubMed]

21.

Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204:1217–26. [DOI] [PubMed] [PMC]

22.

Saidakova EV, Shmagel KV, Korolevskaya LB, Shmage NG, Chereshnev VA. Lymphopenia-induced proliferation of CD4 T-cells is associated with CD4 T-lymphocyte exhaustion in treated HIV-infected patients. Indian J Med Res. 2018;147:376–83. [DOI] [PubMed] [PMC]

23.

Pereira-Manfro WF, Silva GPD, Costa PR, Costa DA, Ferreira BDS, Barreto DM, et al. Expression of TIGIT, PD-1 and HLA-DR/CD38 markers on CD8-T cells of children and adolescents infected with HIV and uninfected controls. Rev Inst Med Trop Sao Paulo. 2023;65:e14. [DOI] [PubMed] [PMC]

24.

Scharf L, Tauriainen J, Buggert M, Hartogensis W, Nolan DJ, Deeks SG, et al. Delayed Expression of PD-1 and TIGIT on HIV-Specific CD8 T Cells in Untreated HLA-B*57:01 Individuals Followed from Early Infection. J Virol. 2020;94:e02128–19. [DOI] [PubMed] [PMC]

25.

Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, et al. CD4⁺ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12:e1005761. [DOI] [PubMed] [PMC]

26.

Vlasova VV, Saidakova EV. The expression patterns of the inhibitory receptors PD-1 and TIGIT on CD4⁺ and CD8⁺ T lymphocytes at different stages of differentiation. Russ J Immunol. 2024;27:553–8. [DOI]

27.

Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol. 2021;12:726419. [DOI]

28.

Marino A, Zafarana G, Ceccarelli M, Cosentino F, Moscatt V, Bruno G, et al. Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience. Diagnostics (Basel). 2021;11:2336. [DOI] [PubMed] [PMC]

29.

Gobran ST, Pagliuzza A, Khedr O, Fert A, Chomont N, Bruneau J, et al. DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people. J Virol. 2023;97:e0110523. [DOI] [PubMed] [PMC]

30.

Ryscavage P, Hussien S, Seung H, Hynicka L. CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment. HIV Med. 2024;25:622–7. [DOI] [PubMed]

31.

Hartling HJ, Gaardbo JC, Ronit A, Salem M, Laye M, Clausen MR, et al. Impaired Thymic Output in Patients with Chronic Hepatitis C Virus Infection. Scand J Immunol. 2013;78:378–86. [DOI] [PubMed]

32.

Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection. J Infect Dis. 2011;203:635–45. [DOI] [PubMed] [PMC]

33.

Silva SL, Sousa AE. Establishment and Maintenance of the Human Naïve CD4⁺ T-Cell Compartment. Front Pediatr. 2016;4:119. [DOI]

34.

Okoye AA, Rohankhedkar M, Abana C, Pattenn A, Reyes M, Pexton C, et al. Naive T cells are dispensable for memory CD4⁺ T cell homeostasis in progressive simian immunodeficiency virus infection. J Exp Med. 2012;209:641–51. [DOI] [PubMed] [PMC]

35.

Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, et al. High Levels of Chronic Immune Activation in the T-Cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin Treatment. J Virol. 2009;83:11407–11. [DOI] [PubMed] [PMC]

36.

Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71. [DOI] [PubMed]

37.

Ghiglione Y, Polo ML, Urioste A, Rhodes A, Czernikier A, Trifone C, et al. Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. Open Forum Infect Dis. 2020;7:ofaa115. [DOI] [PubMed] [PMC]

38.

López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, Benmarzouk-Hidalgo OJ, Dominguez-Molina B, Milanés-Guisado Y, et al. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018;218:624–32. [DOI] [PubMed]

39.

Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Poonia B, et al. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients. Hepatol Int. 2019;13:270–6. [DOI] [PubMed] [PMC]

40.

Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun. 2017;1:586–94. [DOI] [PubMed] [PMC]

41.

Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149–63. [DOI] [PubMed] [PMC]

42.

Chaudhary O, Trotta D, Wang K, Wang X, Chu X, Bradley C, et al. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. J Immunother Cancer. 2022;10:e004564. [DOI] [PubMed] [PMC]

43.

Snell LM, McGaha TL, Brooks DG. Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol. 2017;38:542–57. [DOI] [PubMed] [PMC]

44.

Su L. Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice. Curr HIV/AIDS Rep. 2019;16:224–9. [DOI] [PubMed] [PMC]

45.

Swainson LA, Sharma AA, Ghneim K, Ribeiro SP, Wilkinson P, Dunham RM, et al. IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. JCI Insight. 2022;7:e153046. [DOI] [PubMed] [PMC]

46.

Thaney VE, Kaul M. Type I Interferons in NeuroHIV. Viral Immunol. 2019;32:7–14. [DOI] [PubMed] [PMC]

47.

Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338–42. [DOI] [PubMed] [PMC]

48.

Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42. [DOI] [PubMed] [PMC]

49.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, et al. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunol Res. 2019;7:355–62. [DOI]

50.

Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog. 2016;12:e1005349. [DOI] [PubMed] [PMC]